Abstract
Over the last decade, improvements in cancer therapies have prolonged the lives of cancer patients. Despite dramatic advances in imaging technology, surgical techniques, and adjuvant radio - and chemotherapy, the overall prognosis of this disease remains dismal. In light of this, there is an urgent need for the development of more effective therapies that can target residual disseminated tumor burden. Given the heterogeneity of tumors in general, no one strategy is likely to provide a satisfactory treatment regimen. Until the middle of the 20th century, medical treatments were limited to options like drugs, surgery, antibiotics, and radiation, but in the last years stem cells, due to their pathotropism, have become particularly attractive candidates not only to replace damaged tissue in degenerative pathologies, but also to deliver therapeutic molecules in patients with disseminated metastatic cancer. Worldwide there have been over 2000 patent applications involving human and non-human stem cells, of which one quarter refer to embryonic stem cells. Over one third of all stem cell applications and one quarter of all embryonic stem cell applications have been granted. The aim of this review is primarily to focus on the recent development of stem cell patents in cancer treatments.
Keywords: Patent, stem cells, drug, cancer therapy
Recent Patents on Anti-Cancer Drug Discovery
Title: Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Volume: 5 Issue: 1
Author(s): Stefania Navone, Silvia Cristini, Laura Canzi, Eugenio A. Parati and Gloria Invernici
Affiliation:
Keywords: Patent, stem cells, drug, cancer therapy
Abstract: Over the last decade, improvements in cancer therapies have prolonged the lives of cancer patients. Despite dramatic advances in imaging technology, surgical techniques, and adjuvant radio - and chemotherapy, the overall prognosis of this disease remains dismal. In light of this, there is an urgent need for the development of more effective therapies that can target residual disseminated tumor burden. Given the heterogeneity of tumors in general, no one strategy is likely to provide a satisfactory treatment regimen. Until the middle of the 20th century, medical treatments were limited to options like drugs, surgery, antibiotics, and radiation, but in the last years stem cells, due to their pathotropism, have become particularly attractive candidates not only to replace damaged tissue in degenerative pathologies, but also to deliver therapeutic molecules in patients with disseminated metastatic cancer. Worldwide there have been over 2000 patent applications involving human and non-human stem cells, of which one quarter refer to embryonic stem cells. Over one third of all stem cell applications and one quarter of all embryonic stem cell applications have been granted. The aim of this review is primarily to focus on the recent development of stem cell patents in cancer treatments.
Export Options
About this article
Cite this article as:
Navone Stefania, Cristini Silvia, Canzi Laura, Parati A. Eugenio and Invernici Gloria, Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702235
DOI https://dx.doi.org/10.2174/157489210789702235 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Relevance of Dyslipidaemia and its Consequences in Periodontal Patients with Co-Existing Cardiovascular Disease and Diabetes Mellitus: Therapeutic Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Diuretics in the Treatment of Elderly Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry What We Learnt from Randomized Clinical Trials and Cohort Studies of Antioxidant Vitamin? : Focus on Vitamin E and Cardiovascular Disease
Current Pharmaceutical Biotechnology Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Preface: MicroRNA as Disease Biomarkers
MicroRNA Identification and Quantitation of Some Characteristic Phenolic Compounds in Elderberry Juice by HPLC with Coulometric Electrode Array Detection
Current Bioactive Compounds Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation
Current Drug Targets Pulmonary Rehabilitation as Evaluated by Clinical Trials: An Overview
Reviews on Recent Clinical Trials Atheromatosis Extent in Coronary Artery Disease is not Correlated with Apolipoprotein-E Polymorphism and its Plasma Levels, but Associated with Cognitive Decline
Current Alzheimer Research HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design Non-Vitamin K Oral Anticoagulants (NOACs) A Review of Clinical Management and Laboratory Issues
Current Vascular Pharmacology The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews